Product Pipeline
Ambit is currently in product development of the following:
» Quizartinib (FLT3/KIT) » AC480 (panHER) » AC430 (JAK2) » CEP32496 (BRAF) » CSF1R ProgramQuizartinib (formerly AC220)
- A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status
Status: Complete - Phase 2 Study for AC220 to Treat Acute Myeloid Leukemia (AML)
Status: Active, Not Recruiting - Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors
Status: Active, Recruiting Patients - A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia
Status: Active, Recruiting Patients - A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220 or the CXCR4 Inhibitor Plerixafor With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. (AML18 Pilot)
Status: Not yet recruiting
AC480
- Safety Study for Intravenous (IV) AC480 (AC480IV) to Treat Advanced Solid Tumors
Status: Active, Recruiting Patients - Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma
Status: Active, Not Recruiting Patients